RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans

Angiogenesis

Volumn 15, Issue 4, 2012, Pages 727-744

  Suffee, N ^a   Hlawaty, H ^a   Meddahi Pelle, A ^a   Maillard, L ^a   Louedec, L ^b   Haddad, O ^a   Martin, L ^c   Laguillier, C ^a,d   Richard, B ^a   Oudar, O ^a   Letourneur, D ^a   Charnaux, N ^a,d   Sutton, A ^a,d  

^a UNIVERSITÉ PARIS 13   (France)

^b BICHAT HOSPITAL   (France)

^c DIF   (France)

^d HÔPITAL JEAN VERDIER   (France)

Author keywords

Angiogenesis; Endothelial cells; Glycosaminoglycan; MMP; RANTES; VEGF

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GELATINASE B; GLYCOSAMINOGLYCAN; HERMES ANTIGEN; PROTEOHEPARAN SULFATE; RANTES; SYNDECAN 1; SYNDECAN 4; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL MIGRATION; CELL SPREADING; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; RAT;

RATTUS;

EID: 84875055872     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9285-x     Document Type: Article

References (49)

1. Braunersreuther V, Mach F, Steffens S (2007) The specific role of chemokines in atherosclerosis. Thromb Haemost 97:714-721. (Pubitemid 46804314)
2. Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515-581.
3. Van Hinsbergh V, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78:203-221.
4. Salcedo R, Oppenheim JJ (2003) Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10:359-370. (Pubitemid 39004262)
5. Khurana R, Simons M, Martin JF, Zachary IC (2005) Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112:1813-1824. (Pubitemid 41368158)
6. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621. (Pubitemid 43209108)
7. Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C (2005) Differential and additive effects of plateletderived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 78:435-441. (Pubitemid 41061315)
8. Hayes IM, Jordan NJ, Towers S et al (1998) Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 18:397-403. (Pubitemid 28125634)
9. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM (1996) RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 15:1194-1199. (Pubitemid 26428394)
10. Von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C (2001) RANTES RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103:1772-1777. (Pubitemid 32291415)
11. Proudfoot AE, Handel TM, Johnson Z et al (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100: 1885-1890. (Pubitemid 36254543)
12. Braunersreuther V, Pellieux C, Pelli G et al (2010) Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol 48:789-798.
13. Segerer S, Johnson Z, Rek A et al (2009) The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function. Mol Immunol 46:2533-2538.
14. Solari R, Offord RE, Remy S et al (1997) Receptor-mediated endocytosis of CC-chemokines. J Biol Chem 272:9617-9620. (Pubitemid 27171618)
15. Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C (2003) Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 102:1985-1988. (Pubitemid 37122370)
16. Johnson Z, Kosco-Vilbois MH, Herren S et al (2004) Interference with heparin binding and oligomerization creates a novel antiinflammatory strategy targeting the chemokine system. J Immunol 173:5776-5785. (Pubitemid 39392167)
17. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT (2002) Serum profiles of CC chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 22:223-229. (Pubitemid 34275490)
18. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94:253-261. (Pubitemid 38197459)
19. Barcelos LS, Coelho AM, Russo RC et al (2009) Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in disc-induced inflammatory angiogenesis in mice. Microvasc Res 78:148-154.
20. Bernardini G, Ribatti D, Spinetti G et al (2003) Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273:83-101. (Pubitemid 36078465)
21. Charni F, Friand V, Haddad O et al (2009) Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 1790:1314-1326.
22. Vita C, Drakopoulou E, Ylisastigui L et al (2002) Synthesis and characterization of biologically functional biotinylated RANTES. J Immunol Methods 266:53-65. (Pubitemid 34804672)
23. Korff T, Augustin HG (1998) Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143:1341-1352. (Pubitemid 28559834)
24. Davis GE, Camarillo CW (1996) An alpha 2 beta 1 integrindependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res 224:39-51. (Pubitemid 26116886)
25. Bayless KJ, Davis GE (2003) Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices. Biochem Biophys Res Commun 12:903-913. (Pubitemid 37490902)
26. Sutton A, Friand V, Brule-Donneger S et al (2007) Stromal cellderived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 5:21-33.
27. Hlawaty H, Suffee N, Sutton A et al (2011) Low molecular weight fucoidan prevents intimal hyperplasia in rat injured thoracic aorta through the modulation of matrix metalloproteinase-2 expression. Biochem Pharmacol 81:233-243.
28. Feldman LJ, Mazighi M, Scheuble A et al (2001) Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation 103(25):3117-3122. (Pubitemid 32587860)
29. Park BH, Song KJ, Yoon SJ et al (2011) Acceleration of spinal fusion using COMP-angiopoietin 1 with allografting in a rat model. Bone 49:447-454.
30. Elcin AE, Elcin YM (2006) Localized angiogenesis induced by human vascular endothelial growth factor-activated PLGA disc. Tissue Eng 12:959-968. (Pubitemid 43726536)
31. Willard M, Liang K, Yoon Y, Kang S, Shim H (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359:716-722. (Pubitemid 46908803)
32. Varney ML, Olsen KJ, Mosley RL, Singh RK (2005) Paracrine regulation of vascular endothelial growth factor-a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res 11:674-683. (Pubitemid 43010522)
33. Jain RK, Finn AV, Kolodgie FD et al (2007) Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 4:491-502. (Pubitemid 47316647)
34. Von Luettichau I, Nelson PJ, Pattison JM et al (1996) RANTES chemokine expression in diseased and normal human tissues. Cytokine 8:89-98. (Pubitemid 26110942)
35. Azenshtein E, Luboshits G, Shina S (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093-1102. (Pubitemid 34160293)
36. Suffee N, Richard B, Hlawaty H, Oudar O, Charnaux N (2011) Angiogenic properties of the chemokine RANTES/CCL5. Biochem Soc Trans 39:1649-1653.
37. Westerweel PE, Rabelink TJ, Rookmaaker MB, Gröne HJ, Verhaar MC (2008) RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy. Thromb Haemost 99:794-795. (Pubitemid 351694243)
38. Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J (2003) Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci 44:590-593. (Pubitemid 36159703)
39. Cochain C, Rodero MP, Vilar J (2010) Regulation of monocyte subset systemic levels by distinct chemokine receptors controls post-ischaemic neovascularization. Cardiovasc Res 88:186-195.
40. Zernecke A, Shagdarsuren E, Weber C (2008) Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28: 1897-1908.
41. Son KN, Hwang J, Kwon BS, Kim J (2006) Human CC chemokine CCL23 enhances expression of matrix metalloproteinase- 2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun 340:498-504. (Pubitemid 43021776)
42. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, Gattegno L (2006) The shedding of syndecan-4 and syndecan- 1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase- 9. Glycobiology 16:488-501. (Pubitemid 43779045)
43. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25:201-209. (Pubitemid 38372168)
44. Von Hundelshausen P, Petersen F, Brandt E (2007) Plateletderived chemokines in vascular biology. Thromb Haemost 97:704-713.
45. Rookmaaker MB, Verhaar MC, de Boer HC et al (2007) Met- RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo. Am J Physiol Renal Physiol 293:624-630.
46. Charnaux N, Brule S, Chaigneau T et al (2005) RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology 15:119-130. (Pubitemid 40227917)
47. Slimani H, Charnaux N, Mbemba E, Saffar L, Vassy R, Vita C, Gattegno L (2003) Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochim Biophys Acta 1617:80-88. (Pubitemid 37456715)
48. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C (2001) Structural and functional analysis of the RANTESglycosaminoglycans interactions. Biochemistry 40:6303-6318. (Pubitemid 32472719)
49. Proudfoot AE, Fritchley S, Borlat F et al (2001) The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 276:10620-10626. (Pubitemid 38089230)